Successful salvage of primary progressive Hodgkin lymphoma with the combination of post‐transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition

Belia, Marina; Chatzidimitriou, Chrysovalantou; Rondogianni, Phivi; Petsa, Panayiota; Efstathopoulou, Maria; Konstantinou, Eliana; Arapaki, Maria; Asimakopoulos, John; Plata, Eleni; Konstantopoulos, Kostas; Angelopoulou, Maria K.; Vassilakopoulos, Theodoros P.

doi:10.1002/hon.2801

Cited by 3 publications

(1 citation statement)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Salvage RT has also been explored in combination with systemic therapy. A combination of RT with BV [ 90 ] or immunotherapy has led to CR among R/R cHL patients, though in small case series or retrospective studies [ 91 , 92 , 93 ].…”

Section: Salvage Radiationmentioning

confidence: 99%

Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin’s Lymphoma: So Many Options, How to Choose?

Takiar

Karimi

2022

Cancers

View full text Add to dashboard Cite

The treatment landscape for relapsed/refractory classical Hodgkin’s lymphoma (cHL) has evolved with the introduction of several novel agents. Historically, the standard of care for relapsed cHL was salvage chemotherapy followed by autologous stem cell transplant (ASCT). However, many patients are ineligible for ASCT or will have poor responses to salvage chemotherapy and ASCT. Brentuximab vedotin (BV) and checkpoint inhibitors (nivolumab/pembrolizumab) were initially approved in the post-ASCT setting. However, as a result of excellent responses and durable outcomes in this setting, they are now being studied and explored in earlier lines of therapy. Additionally, these agents are also being studied for post-transplant consolidation and maintenance with promising results in improving progression-free survival. We will review current salvage therapy options involving these novel agents and provide comparisons between regimens to aid the clinician in selecting the appropriate salvage regimen for patients who progress after first-line therapy.

show abstract